Company: BIAF
Filing Date: 2025-05-07
Form Type: 424B4
Source: 0001641172-25-008977
Chunk: 167

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-07
Form: 424B4
Chunk 167
---
, both of which will be filed as exhibits to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the Warrant Agent Agreement, including the annexes thereto, and the form of May 2025 Warrant for a complete description of the terms and conditions of the May 2025 Warrants.

Warrant Stockholder Approval

The May 2025 Warrants are exercisable after issuance.

We have agreed to hold a stockholders’ meeting no later than 90 days from the closing date of this offering in order to seek Warrant Stockholder Approval. If we do not obtain Warrant Stockholder Approval at the first meeting, the Company shall call a meeting every three (3) months thereafter to seek Stockholder Approval until the earlier of the date Stockholder Approval is obtained or the May 2025 Warrants are no longer outstanding. We cannot assure you that we will be able to hold the meeting in this timeframe or obtain Stockholder Approval. In the event that we are unable to obtain the Warrant Stockholder Approval, the Anti-Dilution Adjustment will not be permitted. “Warrant Stockholder Approval” means approval from the stockholders of the Company: (a) of Anti-Dilution Adjustments and (b) to an increase in the number of authorized shares of Common Stock to 350,000,000 shares of Common Stock under the Company’s Certificate of Incorporation, as amended.

Duration and Exercise Price

Each May 2025 Warrant offered hereby will have an exercise price of $0.352 per share (110% of the combined public offering price per share of Common Stock and accompanying May 2025 Warrant). The May 2025 Warrants will expire on the five-year anniversary of the later of the Stockholder Approval Notice Date and the effective date of the filing of the Certificate of Amendment. The exercise price and number of shares of Common Stock issuable upon exercise of the May 2025 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price, provided however that, in the event of a reverse stock split, the number of shares underlying the May 2025 Warrants and the exercise price thereof will each be appropriately adjusted according to the reverse stock split ratio. The May 2025 Warrants will be issued separately from the Common Stock and Pre-Funded Warrants and may be transferred separately immediately thereafter. The exercise price is also